Belgian startup Camel-IDS, a VUB spin-off company that was established in 2014, has raised €37 million for developing cancer-targeted radio-pharmaceuticals. The funding was carried out in a Series A investment round that was led by V-Bio Ventures (Belgium) and Gimv (Belgium) and assisted by the co-lead investors HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel) and BioMedPartners (Switzerland). The event also witnessed participation from existing investors.
Notably, Christina Takke from V-Bio, Karl Naegler from Gimv, Mårten Steen from HealthCap, Morten Graugaard Døssing from Novo Seeds and Ohad Hammer from Pontifax will join the board of directors for the due process of financing the start-up’s cancer research initiatives.